Advanced search
Publication Cover
OncoTargets and Therapy Volume 10, 2017 - Issue
Submit an article Journal homepage
50
Views
25
CrossRef citations to date
0
Altmetric
Case Series

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma

Shen-Cun Fang1 Department of Respiratory Medicine Center, Nanjing Chest Hospital;2 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of China
,
Hai-Tao Zhang1 Department of Respiratory Medicine Center, Nanjing Chest Hospital
,
Ying-Ming Zhang1 Department of Respiratory Medicine Center, Nanjing Chest HospitalCorrespondence[email protected]
&
Wei-Ping Xie2 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People’s Republic of ChinaCorrespondence[email protected]
Pages 447-452 | Published online: 18 Jan 2017

Citations (25)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Xinran Ma, Ling Li, Lei Zhang, Xiaorui Fu, Xin Li, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Xiaoyan Feng, Yu Chang, Zhiyuan Zhou, Feifei Nan, Jieming Zhang, Zhaoming Li & Mingzhi Zhang. (2020) Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study. Drug Design, Development and Therapy 14, pages 275-284.
Read now
Guohe Lin, Bicheng Wang, Xiuwei Wu, Tong Sun, Lili Chen, Canliang Lu & Nianfei Wang. (2020) Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma. Cancer Management and Research 12, pages 11523-11526.
Read now
Shen-Cun Fang, Wen Huang, Ying-Ming Zhang, Hai-Tao Zhang & Wei-Ping Xie. (2019) Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib. OncoTargets and Therapy 12, pages 985-992.
Read now
Deze Zhao, Helei Hou & Xiaochun Zhang. (2018) Progress in the treatment of solid tumors with apatinib: a systematic review. OncoTargets and Therapy 11, pages 4137-4147.
Read now
Xiaofen Li, Xia Li, Xuefeng Fang & Ying Yuan. (2018) Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma. OncoTargets and Therapy 11, pages 4047-4050.
Read now
Fengying Wu, Shijia Zhang, Guanghui Gao, Jing Zhao, Shengxiang Ren & Caicun Zhou. (2018) Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review. Cancer Biology & Therapy 19:3, pages 141-144.
Read now
Da-xiong Zeng, Chang-guo Wang, Jian-an Huang & Jun-hong Jiang. (2017) Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation. OncoTargets and Therapy 10, pages 4269-4272.
Read now

Articles from other publishers (18)

Hang-Ping Wei, Jie Mao & Zu-Liang Hu. (2022) Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report. World Journal of Clinical Cases 10:11, pages 3593-3600.
Crossref
Xiaofang Ying, Huali Liu, Mingwei Wang, Min Peng, Peng Ruan, Vivek Verma & Guang Han. (2020) Clinical Response to Apatinib Combined With Brain Radiotherapy in EGFR Wild-Type and ALK-Negative Lung Adenocarcinoma With Multiple Brain Metastases. Frontiers in Oncology 10.
Crossref
Meijuan Huang, Youling Gong, Jiang Zhu, Yi Qin, Feng Peng, Li Ren, Zhenyu Ding, Yongmei Liu, Chengzhi Cai, Yongsheng Wang & You Lu. (2019) A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC. Investigational New Drugs 38:2, pages 478-484.
Crossref
Mingtao Liu, Hui Li, Xiuxiu Wang, Lijun Jing, Peng Jiang & Yu Li. (2020) Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients. Cancer Medicine 9:8, pages 2660-2673.
Crossref
Na Wang, Shubo Chen, Dengxiang Liu, Jun Guo, Yawei Sun, Juping Zhang, Qian Kong & Lili He. (2020) Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism. Saudi Journal of Biological Sciences 27:2, pages 606-610.
Crossref
Jian Li, Xiwen Tong & Hongtao Li. (2020) Efficacy and safety of apatinib monotherapy in elderly patients with advanced metastatic non-small cell lung cancer. Indian Journal of Cancer 57:1, pages 13.
Crossref
Jing Tang, Xu Yong Li, Jing Bo Liang, De Wu, Li Peng & Xiaobing Li. (2019) Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 27:6, pages 635-641.
Crossref
Da-xiong Zeng, Wei Lei, Chang-guo Wang, Jian-an Huang & Jun-hong Jiang. (2018) Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma. Cancer Chemotherapy and Pharmacology 83:3, pages 439-442.
Crossref
Jin Liu, Yulong Zheng & Nong Xu. (2019) Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer. Medicine 98:5, pages e14328.
Crossref
Di Wu, Li Liang, Ligong Nie, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Xiaoling Chen, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Jieran Long, Yang Wang, Ziran Zhang, Tao Xin & Jian Fang. (2018) Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC. Asia-Pacific Journal of Clinical Oncology 14:6, pages 446-452.
Crossref
Zedong Du, Yanxin Yu, Dajun Wu, Guangyu Zhang, Yang Wang, Liang He & RongQin Meng. (2018) Apatinib for salvage treatment of advanced malignant pleural mesothelioma. Medicine 97:45, pages e13105.
Crossref
Dexiang Yang, Ranran Dai, Qi Zhang & Ping Fang. (2018) Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review. Saudi Journal of Biological Sciences 25:5, pages 888-894.
Crossref
Pinghui Xia, Jinlin Cao, Xiayi Lv, Luming Wang, Wang Lv & Jian Hu. (2018) Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation. Thoracic Cancer 9:5, pages 656-661.
Crossref
Shencun Fang, Meiling Zhang, Guihong Wei & Kai-Hua Lu. (2017) Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR. Oncotarget 9:6, pages 7175-7181.
Crossref
Wen-Chang Yu, Kong-Zhi Zhang, Shi-Guang Chen & Wei-Fu Liu. (2018) Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma. Medicine 97:3, pages e9704.
Crossref
Shuliang Liu, Lingfei Su, Xuri Mu, Yubo Shi, Aifeng Zhang & Xingping Ge. (2018) Apatinib inhibits macrophage-mediated epithelial–mesenchymal transition in lung cancer. RSC Advances 8:38, pages 21451-21459.
Crossref
Da-Xiong Zeng, Chang-Guo Wang, Wei Lei, Jian-An Huang & Jun-Hong Jiang. (2017) Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma. Oncotarget 8:39, pages 66248-66253.
Crossref
. (2017) Apatinib. Reactions Weekly 1645:1, pages 40-40.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.